The market of inferior vana cava filters is majorly driven by rising incidences of cardiovascular diseases globally. According to World Health Organization, about 17.3 million people died from cardiovascular disease (CVD) in 2008 and the number is expected to reach 23.3 million by 2030. This increase in number of patients diagnosed with cardiovascular diseases across the world will boost the global inferior vena cava filters market. In addition, positive initiatives by government and private organization to increase awareness about this device will drive the market growth of inferior vena cava filters. For example, in May 2014, U.S. Food and drug administration issued post market surveillance study for inferior vena cava filters. This study provides information about the implementation of these filters along with the risk of pulmonary embolism. Thus, these types of efforts will increase the uptake of inferior vena cava filters hence drives the market growth. Moreover, consistent launch of new products by key companies will further drive the market growth of inferior vana cava filters. For example, in January 2014, Argon Medical Devices, Inc. announced that the U.S.FDA has cleared Option ELITE retrievable inferior vena cava (IVC) filter. This device is featured with new over-the-wire delivery technique that enables physicians to safely deliver the filter to a patient’s inferior vana cava by following the path of a guide wire. Thus, these types of introduction will increase the acceptance of these devices and hence stimulates the market growth. However, high cost of the product will hamper the market growth in near future.
Request a PDF Brochure with Report Analysis:
Inferior Vena Cava (IVC) Filters are small, cage like devices and commonly used to capture blood clots into the inferior vana cava. These medical devices are inserted into inferior vana cava in order to prevent risk of pulmonary emboli and to prevent them from reaching to the lungs. Inferior vana cava is the main vessel that returns blood from the lower half of the body to the heart. Inferior vana cava filters are usually placed in the patient when anticoagulant therapy cannot be effective at the risk of pulmonary embolism. Commercially these filters are available either to implant permanently or temporarily.
Geographically, North America and Europe dominates the global inferior vena cava filters market due to increasing patient population suffering from cardiovascular diseases, lack of physical activity and unhealthy diet. Europe is considered as the second largest market of inferior vena cava filters. The growth of inferior vena cava filters market in Europe is majorly attributed to the aging population. According to Eurostat (European Commission) report published in 2013, around 17.8% of the European population were aged 65 years and above. In addition, India, South East Asia and China are the emerging markets for inferior vena cava filters because of positive initiative by government in Asia-Pacific regions toward healthcare infrastructure.
Various key players contributing to the global inferior vena cava filters market comprises Baxter International Inc., Fukuda Denshi Co., Ltd., Lidco Group Plc, Accellent, Inc., All Pro Corporation, Arterial Remodeling Technologiesuscome Limited, Biosensors International Group, Ltd., Fudan University Zhongshan Hospital, Cardiva Medical, Inc., 3M Healthcare, Abbott Laboratories and others.
Browse Full Research Report on Inferior Vena Cava (IVC) Filters Market:
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.